Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
123.46
-2.97 (-2.35%)
At close: May 8, 2026, 4:00 PM EDT
123.60
+0.14 (0.11%)
After-hours: May 8, 2026, 7:28 PM EDT
Repligen Revenue
Repligen had revenue of $194.26M in the quarter ending March 31, 2026, with 14.83% growth. This brings the company's revenue in the last twelve months to $763.34M, up 17.36% year-over-year. In the year 2025, Repligen had annual revenue of $738.26M with 16.36% growth.
Revenue (ttm)
$763.34M
Revenue Growth
+17.36%
P/S Ratio
9.12
Revenue / Employee
$381,670
Employees
2,000
Market Cap
6.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 738.26M | 103.82M | 16.36% |
| Dec 31, 2024 | 634.44M | 2.08M | 0.33% |
| Dec 31, 2023 | 632.36M | -169.17M | -21.11% |
| Dec 31, 2022 | 801.54M | 131.00M | 19.54% |
| Dec 31, 2021 | 670.53M | 304.27M | 83.08% |
| Dec 31, 2020 | 366.26M | 96.02M | 35.53% |
| Dec 31, 2019 | 270.25M | 76.21M | 39.28% |
| Dec 31, 2018 | 194.03M | 52.80M | 37.38% |
| Dec 31, 2017 | 141.24M | 36.70M | 35.10% |
| Dec 31, 2016 | 104.54M | 21.00M | 25.14% |
| Dec 31, 2015 | 83.54M | 19.99M | 31.45% |
| Dec 31, 2014 | 63.55M | -4.62M | -6.78% |
| Dec 31, 2013 | 68.17M | 5.90M | 9.48% |
| Dec 31, 2012 | 62.27M | 34.98M | 128.16% |
| Mar 31, 2011 | 27.29M | 6.32M | 30.14% |
| Mar 31, 2010 | 20.97M | -8.39M | -28.58% |
| Mar 31, 2009 | 29.36M | 10.07M | 52.16% |
| Mar 31, 2008 | 19.30M | 5.22M | 37.10% |
| Mar 31, 2007 | 14.07M | 1.16M | 9.01% |
| Mar 31, 2006 | 12.91M | 3.55M | 37.94% |
| Mar 31, 2005 | 9.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Baxter International | 11.32B |
| Solventum | 8.26B |
| Avantor | 6.55B |
| Bausch + Lomb | 5.10B |
| The Cooper Companies | 4.15B |
| Align Technology | 4.10B |
| AptarGroup | 3.87B |
| Envista Holdings | 2.81B |
RGEN News
- 3 days ago - Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference - GlobeNewsWire
- 3 days ago - Repligen price target raised to $160 from $145 at Barclays - TheFly
- 3 days ago - Repligen price target lowered to $165 from $180 at JPMorgan - TheFly
- 4 days ago - Repligen price target lowered to $142 from $152 at Jefferies - TheFly
- 5 days ago - Repligen Earnings Call Transcript: Q1 2026 - Transcripts
- 5 days ago - Repligen raises FY26 EPS view to $1.97-$2.05 from $1.93-$2.10, consensus $1.97 - TheFly
- 5 days ago - Repligen reports Q1 adjusted EPS 48c, consensus 38c - TheFly
- 5 days ago - Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance - GlobeNewsWire